Chaperone-like antibodies targeting misfolded tau protein: New vistas in the immunotherapy of neurodegenerative foldopathies

Journal of Alzheimer's Disease

Volumn 15, Issue 2, 2008, Pages 169-179

  Zilka, Norbert ^a,b   Kontsekova, Eva ^a,b   Novak, Michal ^a,b,c  

^a INSTITUTE OF NEUROIMMUNOLOGY   (Slovakia)

^b Axon Neuroscience Forschungs und Entwicklungs GmbH   (Austria)

^c NONE   (Slovakia)

Author keywords

Alzheimer's disease; Chaperone; Immunotherapy; Misfolded protein; Monoclonal antibody; Tau hyperphosphorylation; Tau truncation

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; AMYLOID BETA PROTEIN; ANTHRAQUINONE DERIVATIVE; CEVIMELINE; CHAPERONE; CYANINE DYE; DIAMINOPHENOTHIAZINE DERIVATIVE; GELDANAMYCIN; LITHIUM CHLORIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY RTA 1; MONOCLONAL ANTIBODY RTA 2; MUSCARINIC M1 RECEPTOR AGONIST; PACLITAXEL; PHENOTHIAZINE DERIVATIVE; PHOSPHOPEPTIDE; POLYPHENOL DERIVATIVE; PORPHYRIN DERIVATIVE; PROTEINASE INHIBITOR; ROSCOVITINE; TACROLIMUS; TAU PHOSPHOPEPTIDE; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; DEGENERATIVE DISEASE; DRUG TARGETING; HUMAN; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN PHOSPHORYLATION; REVIEW; TAUOPATHY;

EID: 54249107245     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2008-15203     Document Type: Review

References (100)

1. A.C. Alonso, I. Grundke-Iqbal and K. Iqbal, Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules, Nat Med 2 (1996), 783-787.
2. A.D. Alonso, I. Grundke-Iqbal, H.S. Barra and K. Iqbal, Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau, Proc Natl Acad Sci USA 94 (1997), 298-303.
3. A.D. Alonso, T. Zaidi, M. Novak, H.S. Barra, I. Grundke-Iqbal and K. Iqbal, Interaction of tau isoforms with Alzheimer's disease abnormally hyperphosphorylated tau and in vitro phosphorylation into the disease-like protein, J Biol Chem 276 (2001), 37967-37973.
4. A. Alonso, T. Zaidi, M. Novak, I. Grundke-Iqbal and K. Iqbal, Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments, Proc Natl Acad Sci USA 98 (2001), 6923-6928.
5. C. Andorfer, C.M. Acker, Y. Kress, P.R. Hof, K. Duff and P. Davies, Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms, J Neurosci 25 (2005), 5446-5454.
6. C. Andorfer, Y. Kress, M. Espinoza, R. de Silva, K.L. Tucker, Y.A. Barde, K. Duff and P. Davies, Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem 86 (2003), 582-590.
7. P.V. Arriagada, J.H. Growdon, E.T. Hedley-Whyte and B.T. Hyman, Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease, Neurology 42 (1992), 631-639.
8. A.A. Asuni, A. Boutajangout, D. Quartermain and E.M. Sigurdsson, Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements, J Neurosci 27 (2007), 9115-9129.
9. F. Bard, C. Cannon, R. Barbour, R.L. Burke, D. Games, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, K. Khan, D. Kholodenko, M. Lee, I. Lieberburg, R. Motter, M. Nguyen, F. Soriano, N. Vasquez, K. Weiss, B. Welch, P. Seubert, D. Schenk and T. Yednock, Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease, Nat Med 6 (2000), 916-919.
10. R. Bhat, Y. Xue, S. Berg, S. Hellberg, M. Ormö, Y. Nilsson, A.C. Radesäter, E. Jerning, P.O. Markgren, T. Borgegård, M. Nylöf, A. Giménez-Cassina, F. Hernández, J.J. Lucas, J. Díaz-Nido and J. Avila, Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor ARA014418, J Biol Chem 278 (2003), 45937-45945.
11. R.V. Bhat, S.L. Budd Haeberlein and J. Avila, Glycogen synthase kinase 3: a drug target for CNS therapies, J Neurochem 89 (2004), 1313-1317.
12. X. Bi, T.S. Haque, J. Zhou, A.G. Skillman, B. Lin, C.E. Lee, I.D. Kuntz, J.A. Ellman and G. Lynch, Novel cathepsin D inhibitors block the formation of hyperphosphorylated tau fragments in hippocampus, J Neurochem 74 (2000), 1469-1477.
13. M.L. Billingsley and R.L. Kincaid, Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration, Biochem J 323 (1997), 577-591.
14. L.I. Binder, A.L. Guillozet-Bongaarts, F. Garcia-Sierra and R.W. Berry, Tau, tangles, and Alzheimer's disease, Biochim Biophys Acta 1739 (2005), 216-223.
15. W. Bondareff, C.M. Wischik, M. Novak, W.B. Amos, A. Klug and M. Roth, Molecular analysis of neurofibrillary degeneration in Alzheimer's disease. An immunohistochemical study, Am J Pathol 137 (1990), 711-723.
16. H. Braak and E. Braak, Neuropathological stageing of Alzheimer-related changes, Acta Neuropathol 82 (1991), 239-259.
17. L. Buée, T. Bussìere, V. Buée-Scherrer, A. Delacourte and P.R. Hof, Tau protein isoforms, phosphorylation and role in neurodegenerative disorders, Brain Res Brain Res Rev 33 (2000), 95-130.
18. A. Caccamo, S. Oddo, L.M. Billings, K.N. Green, H. Martinez-Coria, A. Fisher and F.M. LaFerla, M1 receptors play a central role in modulating AD-like pathology in transgenic mice, Neuron 49 (2006), 671-682.
19. A. Castro, S. Conde, M.I. Rodriguez-Franco and A. Martinez, Non-cholinergic pharmacotherapy approaches to the future treatment of Alzheimer's disease, Mini Rev Med Chem 2 (2002), 37-50.
20. T.K. Chaudhuri and S. Paul, Protein-misfolding diseases and chaperone-based therapeutic approaches, FEBS J 273 (2006), 1331-1349.
21. J.L. Cummings, R. Doody and C. Clark, Disease-modifying therapies for Alzheimer disease: challenges to early intervention, Neurology 69 (2007), 1622-1634.
22. C.A. Dickey and L. Petrucelli, Current strategies for the treatment of Alzheimer's disease and other tauopathies, Expert Opin Ther Targets 10 (2006), 665-676.
23. C.A. Dickey, J. Dunmore, B. Lu, J.W. Wang, W.C. Lee, A. Kamal, F. Burrows, C. Eckman, M. Hutton and L. Petrucelli, HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites, FASEB J 20 (2006), 753-755.
24. C.A. Dickey, A. Kamal, K. Lundgren, N. Klosak, R.M. Bailey, J. Dunmore, P. Ash, S. Shoraka, J. Zlatkovic, C.B. Eckman, C. Patterson, D.W. Dickson, N.S. Nahman Jr, M. Hutton, F. Burrows and L. Petrucelli, The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins, J Clin Invest 117 (2007), 648-658.
25. I. Divinski, M. Holtser-Cochav, I. Vulih-Schultzman, R.A. Steingart and I. Gozes, Peptide neuroprotection through specific interaction with brain tubulin, J Neurochem 98 (2006), 973-984.
26. F. Dou, W.J. Netzer, K. Tanemura, F. Li, F.U. Hartl, A. Takashima, G.K. Gouras, P. Greengard and H. Xu, Chaperones increase association of tau protein with microtubules, Proc Natl Acad Sci USA 100 (2003), 721-726.
27. S. Emadi, H. Barkhordarian, M.S. Wang, P. Schulz and M.R. Sierks, Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity, J Mol Biol 368 (2007), 1132-1144.
28. T. Engel, P. Goñi-Oliver, J.J. Lucas, J. Avila and F. Hernández, Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but preformed neurofibrillary tangles do not revert, J Neurochem 99 (2006), 1445-1455.
29. D.N. Ermolenko, A.V. Zherdev and B.B. Dzantiev, Antibodies as specific chaperones, Biochemistry (Mosc) 69 (2004), 1233-1238.
30. A. Fisher, Z. Pittel, R. Haring, N. Bar-Ner, M. Kliger-Spatz, N. Natan, I. Egozi, H. Sonego, I. Marcovitch and R. Brandeis, M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy, J Mol Neurosci 20 (2003), 349-356.
31. A. Fisher, M1 muscarinic agonists target major hallmarks of Alzheimer's disease - an update, Curr Alzheimer Res 4 (2007), 577-580.
32. I. Genis, A. Fisher, D.M. Michaelson Site-specific dephosphorylation of tau of apolipoprotein E-deficient and control mice by M1 muscarinic agonist treatment, J Neurochem 72 (1999), 206-213.
33. P. Giannakopoulos, F.R. Herrmann, T. Bussière, C. Bouras, E. Kövari, D.P. Perl, J.H. Morrison, G. Gold and P.R. Hof, Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease, Neurology 60 (2003), 1495-1500.
34. T. Gómez-Isla, J.L. Price, D.W. McKeel Jr, J.C. Morris, J.H. Growdon and B.T. Hyman, Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease, J Neurosci 16 (1996), 4491-4500.
35. T. Gómez-Isla, R. Hollister, H. West, S. Mui, J.H. Growdon, R.C. Petersen, J.E. Parisi and B.T. Hyman, Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease, Ann Neurol 41 (1997), 17-24.
36. I. Gozes and I. Divinski, The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection, J Alzheimers Dis 6 (2004), S37-S41.
37. I. Gozes, Activity-dependent neuroprotective protein: from gene to drug candidate, Pharmacol Ther 114 (2007), 146-154.
38. I. Grundke-Iqbal, K. Iqbal, Y.C. Tung, M. Quinlan, H.M. Wisniewski and L.I. Binder, Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology, Proc Natl Acad Sci USA 83 (1986), 4913-4917.
39. I. Grundke-Iqbal, K. Iqbal, M. Quinlan, Y.C. Tung, M.S. Zaidi and H.M. Wisniewski, Microtubule-associated protein tau. A component of Alzheimer paired helical filaments, J Biol Chem 261 (1986), 6084-6089.
40. D.P. Hanger, H.L. Byers, S. Wray, K.Y. Leung, M.J. Saxton, A. Seereeram, C.H. Reynolds, M.A. Ward and B.H. Anderton, Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis, J Biol Chem 282 (2007), 23645-23654.
41. V. Heiser, E. Scherzinger, A. Boeddrich, E. Nordhoff, R. Lurz, N. Schugardt, H. Lehrach and E. Wanker, Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: Implications for Huntington's disease therapy, Proc Natl Acad Sci USA 12 (2000), 6739-6744.
42. T. Horiguchi, K. Uryu, B.I. Giasson, H. Ischiropoulos, R. LightFoot, C. Bellmann, C. Richter-Landsberg, V.M. Lee and J.Q. Trojanowski, Nitration of tau protein is linked to neurodegeneration in tauopathies, Am J Pathol 163 (2003), 1021-1031.
43. M. Hrnkova, N. Zilka, Z. Minichova, P. Koson and M. Novak, Neurodegeneration caused by expression of human truncated tau leads to progressive neurobehavioural impairment in transgenic rats, Brain Res 1130 (2007), 206-213.
44. M. Hüll, M. Berger and M. Heneka, Disease-modifying therapies in Alzheimer's disease: how far have we come? Drugs 66 (2006), 2075-2093.
45. K. Iqbal and I. Grundke-Iqbal, Pharmacological approaches of neurofibrillary degeneration, Curr Alzheimer Res 2 (2005), 335-341.
46. K. Iqbal and I. Grundke-Iqbal, Developing pharmacological therapies for Alzheimer disease, Cell Mol Life Sci 64 (2007), 2234-2244.
47. J.S. Jacobsen, P. Reinhart and M.N. Pangalos, Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease, NeuroRx 2 (2005), 612-626.
48. G.V. Johnson and W.H. Stoothoff, Tau phosphorylation in neuronal cell function and dysfunction, J Cell Sci 117 (2004), 5721-5729.
49. T. Katzav-Gozansky, E. Hanan and B. Solomon, Effect of monoclonal antibodies in preventing carboxypeptidase A aggregation, Biotechnol Appl Biochem 23 (1996), 227-230.
50. M. Kitazawa, S. Oddo, T.R. Yamasaki, K.N. Green and F.M. LaFerla, Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease, J Neurosci 25 (2005), 8843-8853.
51. H.W. Klafki, M. Staufenbiel, J. Kornhuber and J. Wiltfang, Therapeutic approaches to Alzheimer's disease, Brain 129 (2006), 2840-2855.
52. K.S. Kosik and H. Shimura, Phosphorylated tau and the neurodegenerative foldopathies, Biochim Biophys Acta 1739 (2005), 298-310.
53. H. Ksiezak-Reding, W.K. Liu and S.H. Yen, Phosphate analysis and dephosphorylation of modified tau associated with paired helical filaments, Brain Res 597 (1992), 209-219.
54. G. Larbig, M. Pickhardt, D.G. Lloyd, B. Schmidt and E. Mandelkow, Screening for inhibitors of tau protein aggregation into Alzheimer paired helical filaments: a ligand based approach results in successful scaffold hopping, Curr Alzheimer Res 4 (2007), 315-323.
55. S. Le Corre, H.W. Klafki, N. Plesnila, G. Hübinger, A. Obermeier, H. Sahagún, B. Monse, P. Seneci, J. Lewis, J. Eriksen, C. Zehr, M. Yue, E. McGowan, D.W. Dickson, M. Hutton and H.M. Roder, An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice, Proc Natl Acad Sci USA 103 (2006), 9673-9678.
56. V.M. Lee and J.Q. Trojanowski, Progress from Alzheimer's tangles to pathological tau points towards more effective therapies now, J Alzheimers Dis 9 (2006), 257-262.
57. M.D. Ledesma, P. Bonay, C. Colaço and J. Avila, Analysis of microtubule-associated protein tau glycation in paired helical filaments, J Biol Chem 269 (1994), 21614-21619.
58. P. Lichtlen and M.H. Mohajeri, Antibody-based approaches in Alzheimer's research: safety, pharmacokinetics, metabolism, and analytical tools, J Neurochem 104 (2008), 859-874.
59. W. Luo, F. Dou, A. Rodina, S. Chip, J. Kim, Q. Zhao, K. Moulick, J. Aguirre, N. Wu, P. Greengard and G. Chiosis, Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies, Proc Natl Acad Sci USA 104, 9511-9516.
60. E.M. Mandelkow and E. Mandelkow, Tau in Alzheimer's disease, Trends Cell Biol 8 (1998), 425-427.
61. E. Mandelkow, M. von Bergen, J. Biernat and E.M. Mandelkow, Structural principles of tau and the paired helical filaments of Alzheimer's disease, Brain Pathol 17 (2007), 83-90.
62. Y. Matsuoka, A.J. Gray, C. Hirata-Fukae, S.S. Minami, E.G. Waterhouse, M.P. Mattson, F.M. LaFerla, I. Gozes and P.S. Aisen, Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage, J Mol Neurosci 31 (2007), 165-170.
63. Y. Matsuoka, Y. Jouroukhin, A.J. Gray, L. Ma, C. Hirata-Fukae, H.F. Li, L. Feng, L. Lecanu, B.R. Walker, E. Planel, O. Arancio, I. Gozes and P.S. Aisen, A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease, J Pharmacol Exp Ther 325 (2008), 146-153.
64. M.P. Mazanetz and P.M. Fischer, Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases, Nat Rev Drug Discov 6 (2007), 464-479.
65. M.L. Michaelis, K.I. Seyb and S. Ansar, Cytoskeletal integrity as a drug target, Curr Alzheimer Res 2 (2005), 227-229.
66. M.L. Michaelis, Ongoing in vivo studies with cytoskeletal drugs in tau transgenic mice, Curr Alzheimer Res 3 (2006), 215-219.
67. H. Nakashima, T. Ishihara, P. Suguimoto, O. Yokota, E. Oshima, A. Kugo, S. Terada, T. Hamamura, J.Q. Trojanowski, V.M. Lee and S. Kuroda, Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies, Acta Neuropathol 110 (2005), 547-556.
68. M. Necula, C.N. Chirita and J. Kuret, Cyanine dye N744 inhibits tau fibrillization by blocking filament extension: implications for the treatment of tauopathic neurodegenerative diseases, Biochemistry 44 (2005), 10227-10237.
69. W. Noble, E. Planel, C. Zehr, V. Olm, J. Meyerson, F. Suleman, K. Gaynor, L. Wang, J. LaFrancois, B. Feinstein, M. Burns, P. Krishnamurthy, Y. Wen, R. Bhat, J. Lewis, D. Dickson and K. Duff, Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo, Proc Natl Acad Sci USA 102 (2005), 6990-6995.
70. M. Novak, R. Jakes, P.C. Edwards, C. Milstein and C.M. Wischik, Difference between the tau protein of Alzheimer paired helical filament core and normal tau revealed by epitope analysis of monoclonal antibodies 423 and 7.51, Proc Natl Acad Sci USA 88 (1991), 5837-5841.
71. M. Novak, J. Kabat and C.M. Wischik, Molecular characterization of the minimal protease resistant tau unit of the Alzheimer's disease paired helical filament, EMBO J 12 (1993), 365-370.
72. M. Novak, Neuroimmunology of Alzheimer's disease, Bratisl Lek Listy 98 (1994), 303-314.
73. M. Pérez, F. Hernández, F. Lim, J. Díaz-Nido and J. Avila, Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model, J Alzheimers Dis 5 (2003), 301-308.
74. M. Pickhardt, Z. Gazova, M. von Bergen, I. Khlistunova, Y. Wang, A. Hascher, E.M. Mandelkow, J. Biernat and E. Mandelkow, Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells, J Biol Chem 280 (2005), 3628-3635.
75. M. Pickhardt, G. Larbig, I. Khlistunova, A. Coksezen, B. Meyer, E.M. Mandelkow, B. Schmidt and E. Mandelkow, Phenylthiazolyl-hydrazide and its derivatives are potent inhibitors of tau aggregation and toxicity in vitro and in cells, Biochemistry 46 (2007), 10016-10023.
76. R. Scatena, G.E. Martorana, P. Bottoni, G. Botta, P. Pastore and B. Giardina, An update on pharmacological approaches to neurodegenerative diseases, Expert Opin Investig Drugs 16 (2007), 59-72.
77. N. Sergeant, A. Delacourte and L. Buée, Tau protein as a differential biomarker of tauopathies, Biochim Biophys Acta 1739 (2005), 179-197.
78. R. Skrabana, M. Skrabanova, N. Csokova, J. Sevcik and M. Novak, Intrinsically disordered tau protein in Alzheimer's tangles: a coincidence or a rule? Bratisl Lek Listy 107 (2006), 354-358.
79. R. Skrabana, J. Sevcik and M. Novak, Intrinsically disordered proteins in the neurodegenerative processes: Formation of tau protein paired helical filaments and their analysis, Cell Mol Neurobiol 26 (2006), 1083-1095.
80. D.B. Solit amd G. Chiosis, Development and application of Hsp90 inhibitors, Drug Discov Today 13 (2008), 38-43.
81. B. Solomon and F. Schwartz, Chaperone-like effect of monoclonal antibodies on refolding of heat-denatured carboxypeptidase A, J Mol Recognit 8 (1995), 72-76.
82. B. Solomon, R. Koppel, E. Hanan and T. Katzav, Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide, Proc Natl Acad Sci USA 93 (1996), 452-455.
83. B. Solomon, R. Koppel, D. Frankel and E. Hanan-Aharon, Disaggregation of Alzheimer beta-amyloid by site-directed mAb, Proc Natl Acad Sci USA 94 (1997), 4109-4112.
84. B. Solomon, Immunological concept in the treatment of Alzheimer's disease, Drug Dev Res 56 (2002), 163-167.
85. B. Solomon, Clinical immunologic approaches for the treatment of Alzheimer's disease, Expert Opin Investig Drugs 16 (2007), 819-828.
86. A.J. Stewart, A. Fox, B.H. Morimoto and I. Gozes, Looking for novel ways to treat the hallmarks of Alzheimer's disease, Expert Opin Investig Drugs 16 (2007), 1183-196.
87. S. Taniguchi, N. Suzuki, M. Masuda, S. Hisanaga, T. Iwatsubo, M. Goedert and M. Hasegawa, Inhibition of heparininduced tau filament formation by phenothiazines, polyphenols, and porphyrins, J Biol Chem 280 (2005), 7614-7623.
88. T. Taniguchi, M. Sumida, S. Hiraoka, K. Tomoo, T. Kakehi, K. Minoura, S. Sugiyama, K. Inaka, T. Ishida, N. Saito and C. Tanaka, Effects of different anti-tau antibodies on tau fibrillogenesis: RTA-1 and RTA-2 counteract tau aggregation, FEBS Lett 579 (2005), 1399-1404.
89. J. Tucholski, J. Kuret and G.V. Johnson, Tau is modified by tissue transglutaminase in situ: possible functional and metabolic effects of polyamination, J Neurochem 73 (1999), 1871-1880.
90. M. von Bergen, P. Friedhoff, J. Biernat, J. Heberle, E.M. Mandelkow and E. Mandelkow, Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure, Proc Natl Acad Sci USA 97 (2000), 5129-5134.
91. A. von Gunten, E. Kövari, C.B. Rivara, C. Bouras, P.R. Hof and P. Giannakopoulos, Stereologic analysis of hippocampal Alzheimer's disease pathology in the oldest-old: evidence for sparing of the entorhinal cortex and CA1 field, Exp Neurol 193 (2005), 198-206.
92. J.Z. Wang, I. Grundke-Iqbal and K. Iqbal, Glycosylation of microtubule-associated protein tau: an abnormal posttranslational modification in Alzheimer's disease, Nat Med 2 (1996), 871-875.
93. G.K. Wilcock and M.M. Esiri, Plaques, tangles and dementia. A quantitative study, J Neurol Sci 56 (1982), 343-356.
94. C.M. Wischik, M. Novak, P.C. Edwards, A. Klug, W. Tichelaar and R.A. Crowther, Structural characterization of the core of the paired helical filament of Alzheimer disease, Proc Natl Acad Sci USA 85 (1988), 4884-4888.
95. C.M. Wischik, M. Novak, H.C. Thøgersen, P.C. Edwards, M.J. Runswick, R. Jakes, J.E. Walker, C. Milstein, M. Roth and A. Klug, Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease, Proc Natl Acad Sci USA 85 (1988), 4506-4510.
96. C.M. Wischik, P.C. Edwards, R.Y. Lai, M. Roth and C.R. Harrington, Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines, Proc Natl Acad Sci USA 93 (1996), 11213-11218.
97. S.D. Yan, X. Chen, A.M. Schmidt, J. Brett, G. Godman, Y.S. Zou, C.W. Scott, C. Caputo, T. Frappier, M.A. Smith et al., Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress, Proc Natl Acad Sci USA 91 (1994), 7787-7791.
98. Y. Yoshiyama, M. Higuchi, B. Zhang, S.M. Huang, N. Iwata, T.C. Saido, J. Maeda, T. Suhara, J.Q. Trojanowski and V.M. Lee, Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model, Neuron 53 (2007), 337-351.
99. N. Zilka, P. Filipcik, P. Koson, L. Fialova, R. Skrabana, M. Zilkova, G. Rolkova, E. Kontsekova and M. Novak, Truncated tau from sporadic Alzheimer's disease suffices to drive neurofibrillary degeneration in vivo, FEBS Lett 580 (2006), 3582-3588.
100. B. Zhang, A. Maiti, S. Shively, F. Lakhani, G. McDonald-Jones, J. Bruce, E.B. Lee, S.X. Xie, S. Joyce, C. Li, P.M. Toleikis, V.M. Lee and J.Q. Trojanowski, Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model, Proc Natl Acad Sci USA 102 (2005), 227-231.